LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors
Translational Lung Cancer Research · 2023-03 · 12 (3) · 510-529
DOI: 10.21037/tlcr-23-39 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Lung Cancer Research, 2023-03. Verfasst von Ziyi He und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China. Die Arbeit wurde bisher 29-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.
Zitieren
APA
He, Z., Feng, W., Wang, Y., Shi, L., Gong, Y., Shi, Y., Shen, S., & Huang, H. (2023). LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors. Translational Lung Cancer Research, 12(3), 510-529. https://doi.org/10.21037/tlcr-23-39
Vancouver
He Z, Feng W, Wang Y, Shi L, Gong Y, Shi Y, et al. LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors. Translational Lung Cancer Research. 2023;12(3):510-529. doi:10.21037/tlcr-23-39
BibTeX
@article{He2023,
author = {He, Ziyi and Feng, Wei and Wang, Yuxuan and Shi, Liang and Gong, Yuhui and Shi, Yichao and Shen, Shiyu and Huang, Haitao},
title = {LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors},
journal = {Translational Lung Cancer Research},
year = {2023},
volume = {12},
number = {3},
pages = {510--529},
doi = {10.21037/tlcr-23-39}
}
EUVIMED